Efficacy of enterocin S760 in treatment of mice with anthrax infection due to Bacillus anthracis M-71

• Published in: Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] Vol. 56; no. 9-10; p. 13
• Main Authors: Svetoch, E A, Borzilov, A I, Eruslanov, B V, Korobova, O V, Kombarova, T I, Levchuk, V P, Teĭmurazov, M G, Stepanshin, Iu G, Marinin, L I, Diatlov, I A
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2011
• Subjects: Animals; Anthrax - drug therapy; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - isolation & purification; Bacillus anthracis - drug effects; Bacteriocins - administration & dosage; Bacteriocins - isolation & purification; Disease Models, Animal; Drug Evaluation, Preclinical; Enterococcus faecium - chemistry; Mice
• ISSN: 0235-2990

The therapeutic efficacy of enterocin S760, a broad spectrum antimicrobial peptide produced by Enterococcus faecium LWP760 was tested on mice infected with Bacillus anthracis M-71 to induce anthrax (second Tsenkovsky's vaccine). Intraperitoneal four-, two- or one-fold administration of the peptide in a dose of 25 mg/kg for 10 days for prophylactic (1 hour after the contamination) and therapeutic (24 hours after the contamination) purposes prevented or cured the infection in 90-100% of the mice versus the 100-percent lethality in the control (untreated animals). The antimicrobial activity of enterocin S760 against B. anthracis M-71 in vivo correlated with activity in vitro. Enterocin S760 is considered a novel promising antimicrobial for the treatment of grampositive and gramnegative infections.